Jones Financial Companies
ADCT icon

Jones Financial Companies’s ADC Therapeutics ADCT Stock Holding History

Jones Financial Companies’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.06K Hold
3,000
– – ﹤0.01% 4287
2026
Q1 		$11.1K Hold
3,000
– – ﹤0.01% 3543
2025
Q4 		$10.6K Hold
3,000
– – ﹤0.01% 3193
2025
Q3 		$10.9K Hold
3,000
– – ﹤0.01% 3045
2025
Q2 		$8.13K Buy
+3,000
New +$6.31K ﹤0.01% 2950

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jones Financial Companies's ADCT Position: Q2 2026 in Review

Jones Financial Companies held its ADC Therapeutics (ADCT) position steady in Q2 2026 at 3,000 shares worth $3.06K. The position accounts for ﹤0.01% of the portfolio, ranked #4287.

Jones Financial Companies first reported a position in ADCT in Q2 2025 and has held it in 5 quarters since. The position peaked at $11.1K in Q1 2026. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Jones Financial Companies held 3,000 shares of ADC Therapeutics worth $3.06K as of Q2 2026.
  • Jones Financial Companies left its ADC Therapeutics share count unchanged in Q2 2026.
  • ADC Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #4287 holding.
  • Jones Financial Companies first reported a position in ADC Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Jones Financial Companies's ADC Therapeutics position peaked at $11.1K in Q1 2026.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.